Industry news

• Growth Point for Pharmaceuticals is Formed in Russia

  01 November 2019 GMP News

  Today, the pharmaceutical industry in Russia needs a new incentive for development. Launched in 2009, the state industry support program Pharma 2020 gave a strong impetus to the development of the medical and pharmaceutical sectors at the initial stage, which showed significant growth in both production and financial indicators. However, now this impetus is gradually dying out – the pharmaceutical sector growth rate has started to decline since 2018, which is not surprising – the stimulating state program expires next year. 

• EY: foreigners see moderate improvement in Russia’s business climate

  31 October 2019 GMP News

  Sixty-one percent of foreign companies have seen an improvement in Russia’s business climate in the past year, the U.S.-Russia Business Council reported, citing a new  Russian-language report  by EY.

• Russia rises in World Bank's Doing Business ranking

  30 October 2019 Marchmont Innovation News

  Russia now ranks 28th in the World Bank’s  2020 Doing Business ranking  of 190 economies, inching up three places from the 2019 ranking to finish ahead of Israel and even Japan but still behind Kazakhstan, a former Soviet Union republic in Central Asia.

• Pharmacy Leaders from Across Europe Commit to Delivering Primary Healthcare for All

  29 October 2019 GMP News

  Today, on the first anniversary of the Global Conference on Primary Health Care in Astana, Kazakstan, where governments committed to strengthening primary health care as a cornerstone of a sustainable health system and universal health coverage, pharmacy leaders and pharmacists representing 37 countries in the European Region have made a commitment to deliver better primary health care through pharmacy. These representatives of the profession are gathered in Ankara, Turkey, at the International Pharmaceutical Federation’s (FIP’s) second regional conference.

• Russia Developed New Ebola Vaccine

  28 October 2019 GMP News

  Russian Federation has developed a new vaccine against the Ebola virus and is ready to supply it to Africa after the vaccine is registered, Russian Healthcare Minister Veronika Skvortsova said during a session of the Russia-Africa Economic Forum.

• Bayer, Pfizer top pharma on social media, but everyone could be doing better: report

  25 October 2019 Beth Snyder Bulik / FiercePharma

  Pharma companies aren’t exactly blowing it on social media, but they’re also not taking full advantage of the platforms. That’s according to a new digital health check-up from Worldcom Public Relations.

• FDA Modified List of Standards for Premarket Device Reviews

  25 October 2019 GMP News

  The modified list of standards published on Wednesday is meant to assist medical device manufacturers that elect to declare conformity with consensus standards to meet certain US Food and Drug Administration (FDA) requirements.

• Lay the Tech Foundation for IPO Success

  24 October 2019 Mike Kean and Billy Tamulynas / Pharmaceutical Executive

  Leaders of early-stage life sciences companies aim to change the world – or at least many people’s lives. And they might. But, before they do, they must focus on less dramatic items like ensuring segregation of duties, enlisting contract research and manufacturing organizations, and controlling burn rates – especially if they want to smooth the private-to-public company transition and set the stage for sustainable growth.

• FDA generic approvals hit a new record, but the effort's not paying off yet

  23 October 2019 Eric Sagonowsky / FirecePharma

  The FDA doesn’t regulate drug prices, but it's been using one of its most important powers—namely, approving more cheap generics—to drive down costs. And in fiscal 2019, it racked up enough of those approvals to set a new record.

• Driving Success in Gene Therapy

  23 October 2019 Greg Rotz, Anup Kharode, Mike DeMarco, Katelin Patterson, Gabrielle Manoff / Pharmaceutical Executive

  As the New Health Economy continues to unfold, the promise of curative or near-curative gene therapies is one of the most exciting developments. The landscape is rapidly advancing, meaning successful development of the drug pipeline is front and center. Players already in the gene therapy space are under pressure to maximize the success of their portfolio while managing the realities of time, talent, and budget constraints. Meanwhile, those looking to enter the space are wondering what it really takes to develop a gene therapy and which capabilities are truly different from those required for traditional R&D.